drug · small molecule

NEXLETOL

updated 3mo ago

by $ESPR Esperion Therapeutics, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.

targets

ATP-citrate synthase

all catalysts(0)

nothing on the calendar yet

Trials studying NEXLETOL

—A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemiarecruitingn=2,000
phase3A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Eventsnot yet recruitingn=103
phase3A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acidnot yet recruitingn=222
—A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemiaactive not recruitingn=2,560
phase3A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)completedn=301
—Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemiaactive not recruitingn=5,000
phase1Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatincompletedn=58
phase3A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemiacompletedn=130

more trials →

News(2)

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
biopharma_dive · 4d ago
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
biospace · 29d ago

brand

NEXLETOL

trade names

Bempedoic acid component of nexlizet, Nexletol, Nilemdo

generic

BEMPEDOIC ACID

MOA

12.1 Mechanism of Action Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors.

indication

1 INDICATIONS AND USAGE NEXLETOL is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). as an adjunct to diet and exercise, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). NEXLETOL, an adenosine triphosphate-citrate lyase (ACL) inhibitor, is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). ( 1 ) as an adjunct to diet and exercise, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 18m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

NEXLETOL

updated 3mo ago

by $ESPR Esperion Therapeutics, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.

targets

ATP-citrate synthase

all catalysts(0)

nothing on the calendar yet

Trials studying NEXLETOL

—A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemiarecruitingn=2,000
phase3A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Eventsnot yet recruitingn=103
phase3A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acidnot yet recruitingn=222
—A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemiaactive not recruitingn=2,560
phase3A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)completedn=301
—Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemiaactive not recruitingn=5,000
phase1Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatincompletedn=58
phase3A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemiacompletedn=130

more trials →

News(2)

Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
biopharma_dive · 4d ago
Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
biospace · 29d ago

brand

NEXLETOL

trade names

Bempedoic acid component of nexlizet, Nexletol, Nilemdo

generic

BEMPEDOIC ACID

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 18m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

NEXLETOL

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying NEXLETOL

News(2)

Report a data issue

comments(0)

NEXLETOL

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying NEXLETOL

News(2)

Report a data issue

comments(0)